CLEVELAND, April 23, 2013 /PRNewswire/ -- D ATATRAK International, Inc. (OTCQX: DTRK), a leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced an Israeli biopharmaceutical company chose to standardize on the D ATATRAK ONE™ clinical research platform for its oncology program. Understanding the benefit of the unified platform, they will utilize multiple products and modules within the software suite – uEDC, including medical coding and uIRT, including both Randomization and Clinical Supplies Management – to reduce the cost of their clinical trials.
"Our new client has an exciting history of developing novel immunotherapy drug products," stated Laurence P. Birch, D ATATRAK's Chairman of the Board and CEO. "Pairing our expansive technology with their innovative approach to drug development, we are able to reduce costs across their oncology drug program as well as accelerate their clinical trial timelines."
D ATATRAK ONE™:The D ATATRAK ONE™ Clinical Research Platform is an easy to use, cloud-based clinical enterprise solution that empowers Sponsors and CROs to efficiently design, deliver and manage clinical trials. From strategy and planning to resource management and study execution needs, clients manage their entire product portfolio in a single system with one username and password. D ATATRAK's unified clinical enterprise solution consists of seven products: uCTMS, uDesign, uEDC, uIRT, uSafety, uTrain and uCDR.Join D ATATRAK Thought Leaders:
- The DATATRAK Blog
- Tweet: New Israeli Client Selects D ATATRAK ONE™ for Oncology Program http://ow.ly/kjkmv
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts